SirBillybob

I didn’t use +1 agree because the first part is not accurate in its finality and the second 2-dose part is also not accurate in the context of historical vaccinia inoculation. However, the simplest guidance is two Mpox vaccinations using MVA-BN, 3rd generation orthopox vaccine, because the association between humoral immunity (antibody titres from MVA-BN, whether historically primed or not by vaccinia that had eradicated Smallpox) and Mpox protection is not established. However, yes, you received Mpox vaccination if you took Jynneos, Imvamune, or Imnavex from 2022 on. Smallpox protection is moot short of a reverse time travel pod. MVA-BN theoretically provides real life protection against a disease that no longer exists, but is authorized for a possible eventual emergence of it. It is essentially a back-up contingency for Smallpox and its effectiveness would only be assessable if Smallpox incidence swung back. It has been used for uptake among lab workers potentially exposed to the broader orthopox virus class. In fact, the parent product, MVA, was briefly considered as a Smallpox pre-vaccine aimed at attenuating the toxicity of earlier generation vaccination but didn’t get off the ground. All we really know is that if Smallpox (variola virus) re-emerged then MVA-BN would probably be protective along with fewer adverse events. Current research differentiates between Smallpox vaccination and Mpox vaccination because antibody titres against Mpox are the important thing. For decades, the interest has been developing vaccination for outbreaks of Mpox, formerly Monkeypox but name-changed due to lack of specificity of primates as the sole disease-vector mammals to which zoonotic transmission is attributable.

On that note, you literally went and told it on the mountain.

I think of limerence or cathexis as a change in condition as much biochemical as cognitive, but neither in arbitrary sequence or necessarily with a central feature of abandonment fear because these psychological states can occur in neutral interactive contexts. The state or term is moot in a way because its existence and quality is no guarantee of a good outcome. The question is one of capacity to experience a sufficient degree of being just overwhelmed enough as opposed to nonchalance. Indifference could be absolute absence of interest, or suppression of interest (in fact either feigned or alternatively successfully shut down) that might otherwise flourish if reciprocated.

Yes, I understand the distinction. However, both have been referenced on a gradient from extreme at one end to simply the messy glue that bonds initially and not necessarily pathologically. The boiling bunny rabbit on the stove won’t quibble about it bring collateral cathected or limerenced damage. Not gonna split hares. 😉

Try to get ahold of this chapter. I found long ago that it contained some interesting insights on how limerence can be overly activated for various functional psychological reasons, on the one hand, or on the other hand suppressed for similar adaptive reasons. It won’t solve a problem necessarily but a lot of people find the ideas relatable. Don’t get caught up in the ‘sexual desire’ labelling; that part is simply illustrative within the context of mismatched desire in primary attachment relationships.

To coin the term falling in love, infatuation etc for want of better descriptors, even limerence may hinge on more than the most fleeting and minimalist of encounters, however plentiful in quantity of new ones. I’m just not sure what the relative contribution to the ejection seat pattern is here. You suggest that you are comparatively subject to being let go? Not sure.

I wonder if somehow the raw material that would aid in determining your true attachment style is somehow paradoxically inaccessible to you in spite of the high volume of introductory interaction.

OP, it seems that nobody has added any new suggestion that you hadn’t already considered or that even the most basically skilled therapist wouldn’t have already covered. In fact, your responses may represent a parallel to the core dynamics : as if that’s sweet of you and I can engage with any input, you add politely, but that’s not the one key idea that could help yet I appreciate it and all but still a mismatch etc. I am not suggesting contrarianism but simply lack of fit of opinion, as mine might also be inadequate. I have tried to extract your central inquiry about your potential. I think it may be whether limerence is possible for you, the state of ‘vapours’ for want of a better term, a pronounced activation of desire for a specific person that persists long enough to build substantial sustainable multidimensional connectivity when the initial but superficial spark naturally fades and morphs into meaningful BF territory or more. You insinuated, though I cannot be sure, that nobody evocative of limerence in you has yet to be subject to its activation in them by you. So it appears that you have an idiosyncratic lack of inclination to limerence (I wasn’t sure whether in principle you are cynical about this human characteristic or pessimistic based on experience to date) or that the two it takes to tango has yet to occur. Essentially, then, have you been excited about any one fellow that did not reciprocate? Then it’s more a matter of kissing more frogs. Alternatively, you may not have the temperament for a lasting romantic connection and the additive value of sequential encounters may be the model you are working with and could be meaningful in its own way if not the ideal.

This topic has the gravity of the ISS, where it has no gravity. If you stink in space can anybody smell it?

Madrid airport is screening for Mpox from Clade I endemic areas. Thailand border control, a bit oddly, has confirmed a single Clade I case and launched flight contact tracing with respect to a European traveller that had been in Africa, yet has mapped ‘high risk’ foreign nationals entering as subject to screening according to the list of about 45 countries for which it requires Yellow Fever vaccination for entrants. This could also mean a traveller not from a YF high risk nation but having recently been in transit. However, there seems to be no scientific basis for the broadening of screening foreign nationals from select South and Central America nations. Also a few more Asian nations initiating arrival screening.

There are a few post-peak reviews of MVA-BN effectiveness, but any article that suggests the benefits of older age is always welcome in my books. Interestingly, a single recent dose among Vaccinia-experienced was just as good as two doses for immune antibody response temporal waning in this small sample, as Bavarian Nordic had already indicated two years ago. I went and received my second dose latently yesterday anyway, due to upcoming travel, screening that could evolve due to possible Clade I seepage globally, and the possible benefit of recorded doses in one’s immunization booklet. I wouldn’t go as far as blithely broadcasting uptake history to any border control agent, however, due to possible overreactive stigmatizing. In a scenario of being detained due to unrelated but elevated body temperature it might come in handy. Study reveals waning antibody response to monkeypox vaccine over time WWW.NEWS-MEDICAL.NET New research to be presented at this year's European Congress of Clinical Microbiology and Infectious Diseases...

Geez! Thanks for the Emily post, Governess. Yes it would be rude and dismissive but that is not the playbook I described. It would be superfluous, and silly in fact as being unnecessarily pre-emptive, to indicate intent to ‘play the field’ prior to the question of private dance coming up. I would have to disown you if witnessing such.😉 Did I indicate abruptly truncating social chit-chat following a few seconds post-greeting? No. These chats may evolve for several minutes duration prior to politely extricating myself. It’s all in the balance of social discourse while not impeding his chances for other prospective employers. I don’t stratify according to private potential versus outright snubbable. My agenda is to be selectively financially deprivational while leaving egos intact. If anything, at times the dancer may seem a little surprised at my attentive borderline flirty ‘betiquette’ where I wasn’t the best bet after all, followed by my gentle migration away into the maddening crowd. I appreciate the laugh, though. I assume you’ve worked the room at a cocktail party but not said ‘well, I’m going to see who else here is worth my attention’, if not intersected with corridors of manned conference booths or speed-dating venues. LOL

A mixologist after our own hearts.

A very pricey advertiser I had hedged on for a while without booking has crossed back over to club dancer income supplementation and it was an unexpected fun (well, discounted, depending on how you look at it) ‘bucket list’ experience. I would probably spring for an off-site hook-up after all, as the sampler was a good forecast. —- “Maybe later” being essentially interpreted by a dancer as ‘no’ now means ‘yes’ a while afterwards is rare and could be seen as poor comportment if you didn’t explicitly signal a follow-up exchange. I would view it in the context of the psychological difficulty of being repeatedly rebuffed, however gently, and his later lobbing back with a mini-micro aggression, as if you had owed him a less ambiguous but obviously more emphatic decline in the first place. It may have worked occasionally and he has nothing to lose. That said, I usually just say, before the private dance interest question even pops up, “Thanks for saying hello” and move away a few steps into the crowd (I stand and circulate as it feels less trapped). I think it might be easier as you have extricated yourself rather than the guy needing to separate from your space following being given your regrets. In my case, I lack ambivalence about whether a private dance is in the cards unless he has already successfully provided in the past, which brings us to … A related topic is a (the) dancer with whom you have previously had good experiences naturally approaching you but you wish to case the joint for other prospects. That calls for a modified exchange of pleasantries, tact, and intent. I have found that they take it in stride and wait for a cue later without circling back for a status review.

Devoured all but This Other Eden (yet to access) this summer. Great pleasure. Prophet Song, devastating, lines right up with current events. The Bee Sting is lengthy but I couldn’t put it down; expansive enough to include a gay subplot. Study for Obedience won Canada’s big honour, the Giller Prize. If I Survive You a story collection.

I think I saved about $10 on the I-books pre-order relative to the formal list price. Can’t wait.

I-Books sample looks worth it. I placed on reserve at my library. Hope it doesn’t burn down first. Plot spoiler: biblical ending holds but that is obvious up front. I suggest reading some brief reviews that will help you to immediately grasp the narrator (plural) structure.

I am getting hot under the collar and it’s not fever. It appears that Health Canada and NACI are dicking around holding out for a viable COVID-Influenza combo vaccination. Yet PfizerBioNTech, Moderna, and Novavax new formulations are all set to go. My interpretation of the reason for the USA FDA’s continuing review of Novavax’ submission is that the just approved mRNA monovalent doses target KP.2 strain specifically while Novavax targets the parent strain JN.1 strain and the company asserts cross-reactivity with KP.2 strain. I was at Montréal’s downtown vaxx centre yesterday and the nurses thought November for any product rollout. Impossible, I hope. Canada had better uncouple vaccination for the two diseases this Fall. Again, makes my blood boil. This year is just a repeat of last year’s delay to October-ish. There are sufficient data precedents.

LOL. I’ve proclaimed that about their Viagra more times than I can recall. Find my brief allowable expletives on X. Pfizer and BioNTech will import their whining about profit margins into price gouging. [Restricted expletive]

It isn’t clinically or operationally relevant because the investigational COVID formulation component is last year’s. Meanwhile, companies are vying for financial gain and authorization entities stalling on the upcoming season’s needed version engineered for FLiRT variant. One can always get a separate robust flu vaccine. If the updated COVID vaccine (or prospective combo) were to arrive late to the party then what good would a two-in-one have been anyway, as a window for influenza cases otherwise preventable via timely flu vaccination will have been left ajar? The study merely began to study proof of concept, and immunogenic potential but not efficacy, at that. If all three targets had been each arbitrarily set at 80% desired success, say, the probability of at least one of three failing would be 49%.

Glad you didn’t fall into the syndrome trap.😉 Oops, I mean I’m.

Have you not been reading in the public domain media simple summaries on the science, surveillance, and logic regarding the two clades of relevance? For Canada, the ratio of vaccinated to those susceptible to Clade I is negligible. MVA-BN uptake rate to date confers extremely minimal overall population coverage. Mpox Clade I does not potentiate Clade IIb incidence. The latter does not piggy-back on the former. I wouldn’t conflate Clade I concerns with the unique Mpox strain related to the current estimated completed subpopulation vaccination uptake you referenced, a 1:3 ratio of those vaccinated to those susceptible to a disease that is essentially in abeyance. The emergence of the more lethal Clade does not poke a different sleeping giant. There is minimal evidence that predicts an upsurge specific to those not yet vaccinated against the originally targeted Clade IIb. Again, any latent residual spread over two years has been very self-limiting and the phenomenon of a few cases that were followed by a substantial peak in 2022 has not recurred. There has been an association between level of behavioural risk and either natural or artificial immunity that accounts for relative control. Moreover, further softening of CoV pandemic boundaries since 2022 has had no effect on Mpox incidence. Therefore, Mpox vaccination to date, even if it had been much more widespread for those at risk, should have very little bearing on an impending Mpox incursion as the total susceptible population is a vastly larger denominator. Any level of uptake and infection shielding among GBMSM would just be absorbable within a scenario of the revised targeted population at risk.

Spain and Israel, being closest in proximity to the Africa with which I am familiar (I didn’t know there were additional Africas) have experienced Mpox. I will be in Spain again this year. I think that the country reports cases officially but if I catch Mpox I will report it in some way. If I go somewhere to report it you may have clairvoyantly predicted that movement, that my Swatch is waterproof, and whether Canada had been annexed by Scandinavia or vice versa along with a merger of any shores not geographically specific to an Africa.

There are 3, and a 4th in development by Moderna. We all got MVA-BN which is one of the 3 but has 3 brand names according to global location, not to be confused with the trifecta of distinct products.

Just touched down in Stockholm, as case possibility beyond Africa was expected eventually. Clade I; the b now seems to be unnecessary given the phylogenetic tree structure. Person travelling from the endemic area. Contained thus far, Sweden reports. Public Health Agency of Canada had weeks ago estimated a 10% chance of arrival here by September, without the same expected spread that had been attributable to GBMSM network transmission of Clade IIb. Preparedness now an obvious benefit.